美股A股
StockGist

Regencell Bioscience Holdings Limited

RGCNASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.
$4.94-3.61%
报价 2026-11-13
市值
$2.45B
EV
$3.11B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -90.7%
$4.78$52.88

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

研究结论

L2 2026-07-01全文 ↓

尚未生成 L3 估值,没有三情景目标价。去生成估值 →

L2 报告格式无法提取要点,请看全文。

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

同行业市值相近 · Drug Manufacturers - Specialty & Generic
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
RGCRegencell Bioscience Holdings Limited$2.45B-3.6%–0%–––
BHCBausch Health Companies Inc.$3.13B+1.2%+6.8%75%–8.9x1.7x
HCMHutchison China Ltd.$2.6B+0.3%+12.2%17%145.0x–234.4x
PRGOPerrigo Company plc$2.25B+0.4%-6.0%30.7%––12.9x
TRLVTrulieve Cannabis Corp.$1.86B-2.2%-13.8%59.9%–6.8x8.2x
SUPNSupernus Pharmaceuticals, Inc.$1.73B+1.8%+26.8%85.7%8.0x3.4x55.3xCheap GARP
ANIPANI Pharmaceuticals, Inc.$1.62B+0.5%+26.6%61.6%13.7x5.6x9.2xCheap GARP
ALVOAlvotech$1.5B-10.3%+3.0%50.7%–––
PAHCPhibro Animal Health Corporation$1.46B+1.4%+5.5%33.2%13.5x8.6x67.4x
同行中位数––+6.1%55.3%13.6x6.8x12.9x

研究全文

财务报表

Metric
2026-06-30
Q4 2026
2025-12-31
Q2 2026
2025-06-30
Q4 2025
2024-12-29
Q2 2025
2024-06-30
Q4 2024
2023-12-30
Q2 2024
2023-06-30
Q4 2023
2022-12-30
Q2 2023
Revenue$0$0$0$0$0$0$0$0
Gross Margin0%0%0%0%0%0%0%0%
Operating Margin0%0%0%0%0%0%0%0%
Net Income$-6.4M$-5.3M$-1.7M$-1.9M$-1,117$-1,033$-2.6M$-3.2M
Diluted EPS-0.01-0.01-0-0-0-0-0.01-0.01
Operating Cash Flow$-5.1M$-2.6M$0$0$-2M$-4M$-2.5M$-5M

研究材料